CTLA4 and melanoma: In a study employing an adenoviral vaccine encoding the gp33-41 epitope of the glycoprotein of lymphocytic choriomeningitis virus (LCMV) to treat gp33-expressing B16-F10 melanoma tumors, blocking CTLA-4 marginally improved tumor control as compared to gp33-adenovirus vaccination alone.